NCT05220813

Brief Summary

To assess the effect of iliohypogastric and ilioinguinal nerve block on the hemodynamic stability ,narcotic consumption and the rate of conversion to general anesthesia in patients undergoing transfemoral transcatheter aortic valve implantation (TF-TAVI).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
88

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Nov 2021

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 11, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

January 22, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 2, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2022

Completed
Last Updated

February 21, 2022

Status Verified

February 1, 2022

Enrollment Period

6 months

First QC Date

January 22, 2022

Last Update Submit

February 4, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • conversion to general anesthesia.

    Conversion to general anesthesia in other than procedure related causes.

    during the procedure (intraoperatively)

Secondary Outcomes (3)

  • propofol dose

    during the procedure (intraoperatively)

  • fentanyl dose

    during the procedure (intraoperatively)

  • sedation score

    during the procedure (intraoperatively)

Study Arms (2)

local anesthetic group (control group)

ACTIVE COMPARATOR

44 patients will receive local infiltration anesthesia.

Drug: Lidocaine

ilioinguinal iliohypogastric group

ACTIVE COMPARATOR

44patients will receive ilioinguinal iliohypogastric nerve blocks

Drug: Bupivacain

Interventions

local infiltration by lidocaine in the surgical site

local anesthetic group (control group)

44patients will receive bupivacaine in ilioinguinal \& iliohypogastric nerve blocks

ilioinguinal iliohypogastric group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing TF-TAVI.
  • Both sexes.
  • Age 18 and above

You may not qualify if:

  • Inability to tolerate supine position as in patients with musculoskeletal disease or back pain, OR in patients with congestive heart failure or with obstructive sleep apnea.
  • Patients with severe pulmonary hypertension (PAP\>60 mmhg)
  • Barrier to communications as language barrier or dementia.
  • Patients' preference of general anesthesia.
  • Surgical consideration as transapical, subclavian approach, extensive TEE requirements.
  • Patients with history of allergy to any drugs used.
  • Patients with psychiatric disease.
  • Patients with neurocognitive or neurodegenerative disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ismail Mohammed Ibrahim

Cairo, 11765, Egypt

RECRUITING

MeSH Terms

Interventions

LidocaineBupivacaine

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Central Study Contacts

ismail M ibrahim, MD

CONTACT

mohamed mohsen mohamed, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

January 22, 2022

First Posted

February 2, 2022

Study Start

November 11, 2021

Primary Completion

May 1, 2022

Study Completion

May 1, 2022

Last Updated

February 21, 2022

Record last verified: 2022-02

Locations